Alkermes Q1 revenue $392.9M; GAAP net loss $66.5M after Avadel acquisition costs

Alkermes plc.

2026-Q1 EPS reported -$0.40 vs consensus -$0.58 ▲ beat (+30.9%)

Q1 total revenues $392.9M, up 28% YoY; GAAP net loss $66.5M vs. income of $22.5M in Q1 2025.
Adjusted EBITDA $80.3M, up from $45.6M YoY; LUMRYZ contributed $39.5M post-Avadel close on Feb 12.
Full-year 2026 GAAP net loss guidance improved to ($70)-($90)M from ($115)-($135)M; total revenue outlook unchanged.
Avadel acquisition closed in Feb; used $775M cash and $1.525B term loans; cash balance now $538M.
Initiated Phase 3 Brilliance studies for alixorexton in narcolepsy type 1 and type 2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alkermes plc. reported the three months ended March 31, 2026 results: revenue $392.9 Million, net income GAAP Net Loss of $66.5 Million. Guidance lowered.

Period: the three months ended March 31, 2026
Revenue: $392.9 Million
Net income: GAAP Net Loss of $66.5 Million
Guidance: lowered
Result: reported results

Exact text from the filing

Alkermes plc Reports First Quarter 2026 Financial Results — First Quarter Revenues of $392.9 Million; GAAP Net Loss of $66.5 Million and Adjusted EBITDA of $80.3 Million

View on SEC.gov

Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.